CoChat

Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease

· 1994 · Archives of Internal Medicine
Cited by 53

The DOI matches its OpenAlex record.

Abstract

BACKGROUND: Because nicotine can cause adverse cardiovascular effects, we assessed the safety of transdermal nicotine for smoking cessation in patients with coronary artery disease. METHODS: This 5-week, double-blind, randomized, placebo-controlled, multicenter study enrolled 156 patients with coronary artery disease who smoked at least one pack of cigarettes daily. Patients were randomized to receive either transdermal nicotine (14 mg/d) or transdermal placebo. After 1 week, patients who had smoked more than seven cigarettes were able to have their dose of blinded study medication increased to 21 mg/d of transdermal nicotine or corresponding placebo. All participants then continued to receive their chosen medication dose for an additional 4 weeks and attended weekly group counseling sessions. Adverse effects, cardiac events, electrocardiographic changes, frequency of angina, other cardiac symptoms, vital signs, and weight were monitored. Serial 24-hour ambulatory electrocardiographic monitoring was performed at one center. Smoking cessation rates were determined from diary reports of no smoking during the last 4 weeks of the study, corroborated weekly by expired breath carbon monoxide levels no higher than 8 ppm. RESULTS: Eight of 79 patients randomized to receive placebo and three of 77 patients randomized to receive transdermal nicotine withdrew during the trial owing to adverse effects (P = .13), most of which were cardiovascular. Transdermal nicotine did not affect angina frequency, overall cardiac symptom status, nocturnal events, arrhythmias, or episodes of ischemic ST segment depression. Smoking cessation was achieved by 36% and 22% of patients receiving transdermal nicotine and placebo, respectively (P < .05). CONCLUSION: Transdermal nicotine was well tolerated by patients with stable coronary artery disease in this trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1001/archinte.154.9.989

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Venue
Archives of Internal Medicine
Publisher
American Medical Association
Published
1994-05-09
Volume
154
Issue
9
Pages
989-995
ISSN
0003-9926 (ISSN-L)
OpenAlex
W4206130140
Cited by
53
References
0
FWCI
0.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.